CL2008003202A1 - Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta. - Google Patents

Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.

Info

Publication number
CL2008003202A1
CL2008003202A1 CL2008003202A CL2008003202A CL2008003202A1 CL 2008003202 A1 CL2008003202 A1 CL 2008003202A1 CL 2008003202 A CL2008003202 A CL 2008003202A CL 2008003202 A CL2008003202 A CL 2008003202A CL 2008003202 A1 CL2008003202 A1 CL 2008003202A1
Authority
CL
Chile
Prior art keywords
strain
bovis
immunogenic composition
mycoplasma bovis
live attenuated
Prior art date
Application number
CL2008003202A
Other languages
English (en)
Inventor
Michael Beck
Jeffrey KNITTEL
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Publication of CL2008003202A1 publication Critical patent/CL2008003202A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA VACUNA QUE COMPRENDE CEPAS BACTERIANAS DE MYCOPLASMA BOVIS ATENUADA AVIRULENTA, DONDE DICHA CEPA SE SELECCIONA DEL GRUPO QUE CONSISTE DE: A) LA CEPA BACTERIANA DE M. BOVIS ATENUADA DEPOSITADA EN LA ATCC CON EL NÚMERO DE ACCESO PTA-8694, B) CUALQUIER CEPA BACTERIANA DE M. BOVIS DESCENDIENTE DE LA CEPA DEPOSITADA EN LA ATCC CON EL NÚMERO DE ACCESO PTA-8694, CAPAZ DE INDUCIR UNA RESPUESTA INMUNE HUMORAL EN UN TERNERO DENTRO DE LOS 14 DIAS DESPUÉS DE LA ADMINISTRACIÓN DE UNA DOSIS VÍA SUBCUTÁNEA O RUTA INTRANASAL DE UN TERNERO, Y DE NO CAUSAR SIGNOS CLÍNICOS NORMALMENTE CAUSADOS POR UNA INFECCIÓN CON UNA CEPA SILVESTRE DE M. BOVIS.
CL2008003202A 2007-10-29 2008-10-28 Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta. CL2008003202A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98348207P 2007-10-29 2007-10-29
US7555208P 2008-06-25 2008-06-25

Publications (1)

Publication Number Publication Date
CL2008003202A1 true CL2008003202A1 (es) 2009-11-27

Family

ID=40591728

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003202A CL2008003202A1 (es) 2007-10-29 2008-10-28 Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.

Country Status (14)

Country Link
US (1) US8652481B2 (es)
EP (1) EP2214702B1 (es)
JP (2) JP2011500093A (es)
KR (2) KR20160095185A (es)
CN (2) CN103667125A (es)
AR (1) AR069087A1 (es)
BR (1) BRPI0819149B1 (es)
CA (1) CA2699218C (es)
CL (1) CL2008003202A1 (es)
MX (1) MX2010003719A (es)
NZ (1) NZ585588A (es)
SG (1) SG185932A1 (es)
UY (1) UY31437A1 (es)
WO (1) WO2009058833A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059437A1 (en) * 2006-09-07 2011-03-10 Boehringer Ingelheim Vetmedica, Inc. Pcr-based genotyping
CL2008003202A1 (es) 2007-10-29 2009-11-27 Boehringer Ingelheim Vetmedica Inc Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.
US8503527B2 (en) 2008-10-03 2013-08-06 Qualcomm Incorporated Video coding with large macroblocks
SG10201506597RA (en) 2008-10-31 2015-10-29 Boehringer Ingelheim Vetmed Use Of Various Antigens Including Antigens From Mycoplasma Bovis In Multivalent Vaccine Composition
UY32570A (es) * 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
PT2938747T (pt) 2012-12-28 2019-08-01 Boehringer Ingelheim Vetmedica Gmbh Método de preparação de uma vacina de micoplasma
AU2013370982C9 (en) 2012-12-28 2019-01-24 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
DK3334454T3 (da) * 2015-08-14 2022-11-14 Zoetis Services Llc Mycoplasma-Bovis-sammensætninger
AU2016380864B2 (en) 2015-12-28 2019-10-31 Boehringer Ingelheim Animal Health USA Inc. M hyo multivalent vaccine and uses thereof
CN105441368B (zh) * 2016-01-19 2019-01-01 福清市默克兽医院 一株牛支原体及其应用
CN107118262A (zh) * 2016-02-24 2017-09-01 华中农业大学 一种牛支原体MbovP579蛋白及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7007A (en) * 1850-01-08 Improvement in machinery for making cotton cordage
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
EP0994944A1 (en) 1997-07-10 2000-04-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated
EP0965639A1 (en) 1998-06-05 1999-12-22 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
AU779280B2 (en) * 1999-03-26 2005-01-13 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
CA2390613A1 (en) 1999-11-08 2001-05-17 Biomune Vaccines for mycoplasma bovis and methods of use
US6548069B2 (en) 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
US20030147914A1 (en) * 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
MXPA03011924A (es) 2001-07-02 2004-03-26 Pfizer Prod Inc Vacuna de micoplasma hyopneumoniae y metodos para reducir la neumonia por mycoplasma bovis en el ganado.
BR0211563A (pt) 2001-08-28 2004-07-13 Pfizer Prod Inc Modelo de infecção por mycoplasma bovis e métodos para administração de m. bovis e para indução de lesões pneumÈnicas do pulmão
DE102004025452A1 (de) 2004-05-19 2006-01-19 Boehringer Ingelheim Vetmedica Gmbh Vakzine enthaltend BVDV
US20070009545A1 (en) 2005-07-07 2007-01-11 Joachim Frey Mycoplasma subunit vaccine
US20110059437A1 (en) 2006-09-07 2011-03-10 Boehringer Ingelheim Vetmedica, Inc. Pcr-based genotyping
US20090068231A1 (en) * 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
CL2008003202A1 (es) 2007-10-29 2009-11-27 Boehringer Ingelheim Vetmedica Inc Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.
EP2320943B1 (en) 2008-07-03 2016-02-17 Iowa State University Research Foundation, Inc. Cattle vaccines
SG10201506597RA (en) 2008-10-31 2015-10-29 Boehringer Ingelheim Vetmed Use Of Various Antigens Including Antigens From Mycoplasma Bovis In Multivalent Vaccine Composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada

Also Published As

Publication number Publication date
US20090130148A1 (en) 2009-05-21
EP2214702A4 (en) 2010-12-22
AU2008318793A1 (en) 2009-05-07
CN101827605A (zh) 2010-09-08
WO2009058833A2 (en) 2009-05-07
JP5789897B2 (ja) 2015-10-07
US8652481B2 (en) 2014-02-18
KR101656301B1 (ko) 2016-09-12
CN103667125A (zh) 2014-03-26
WO2009058833A3 (en) 2009-06-18
KR20160095185A (ko) 2016-08-10
BRPI0819149B1 (pt) 2021-11-23
KR20100084626A (ko) 2010-07-27
MX2010003719A (es) 2010-04-27
CN101827605B (zh) 2016-05-04
EP2214702A2 (en) 2010-08-11
BRPI0819149A2 (pt) 2020-08-25
JP2013223511A (ja) 2013-10-31
CA2699218A1 (en) 2009-05-07
EP2214702B1 (en) 2018-07-04
NZ585588A (en) 2012-09-28
SG185932A1 (en) 2012-12-28
JP2011500093A (ja) 2011-01-06
AR069087A1 (es) 2009-12-30
UY31437A1 (es) 2009-05-29
CA2699218C (en) 2019-09-10

Similar Documents

Publication Publication Date Title
Shen et al. Isolation, identification and pathogenicity of Vibrio harveyi, the causal agent of skin ulcer disease in juvenile hybrid groupers Epinephelus fuscoguttatus× Epinephelus lanceolatus
Arijo et al. Effectiveness of a divalent vaccine for sole, Solea senegalensis (Kaup), against Vibrio harveyi and Photobacterium damselae subsp. piscicida
UY32570A (es) Vacuna viva modificada de mycoplasma bovis mejorada
AR068418A1 (es) Bacteria mycoplasma gallisepticum atenuada, composicion de vacuna, metodos para identificar clones de mycoplasma gallisepticum atenuados y vacunar un animal contra infeccion de mycoplasma gallisepticum
AR127585A1 (es) Vacuna de arn de virus sincicial respiratorio
AR068419A1 (es) Cepas de mycoplasma atenuadas vivas
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
MX2010005014A (es) Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante.
AR069087A1 (es) Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
Kiran et al. Degradation intermediates of polyhydroxy butyrate inhibits phenotypic expression of virulence factors and biofilm formation in luminescent Vibrio sp. PUGSK8
Mo et al. Outbreak of Edwardsiella tarda infection in farm-cultured giant mottled eel Anguilla marmorata in China
Halpern et al. Dependent population dynamics between chironomids (nonbiting midges) and Vibrio cholerae
AR093424A1 (es) Vacunas atenuadas de mannheimia haemolytica y metodos para su elaboracion y uso
Gudmundsdottir et al. Aeromonas salmonicida and A. hydrophila.
CN102994456A (zh) 一种人工合成的s13噬菌体及其应用
CN107384837A (zh) 一株鸡滑液支原体及其应用
CN110257274B (zh) 一种伪结核棒状杆菌致弱方法及应用
Gowrakkal et al. Evaluation of immuno efficiency of hemorrhagic septicemia vaccine strain (vaccine seed)
Lublin et al. Salmonella in Poultry and Other Birds
Eid et al. An overview of the current situation of salmonellosis in pigeons, household chickens, and commercial broilers with a special reference to a customized vaccine developing trial
FI3334454T3 (fi) Mycoplasma bovis -koostumuksia
Ooyama et al. Application of attenuated Lactococcus garvieae strain lacking a virulence‐associated capsule on its cell surface as a live vaccine in yellowtail Seriola quinqueradiata Temminck and Schlegel
Ezzat et al. Prevalence and Molecular detection of some virulence genes among Salmonella species Isolated from Poultry
Al Kareem et al. In-vivo pathogenicity of aerolysin toxin of Aeromonas hydrophila isolated from diarrhea patients in Thi-Qar province
Shinoda et al. International collaborative research on infectious diseases by Japanese universities and institutes in Asia and Africa, with a special emphasis on J-GRID